{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:47:57Z","timestamp":1787780877168,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00108-022-01419-4","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T19:06:49Z","timestamp":1668539209000},"page":"1250-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Was ist gesichert in der Therapie des Kolonkarzinoms","What is confirmed in the treatment of colon cancer?"],"prefix":"10.1007","volume":"63","author":[{"given":"Florian","family":"Lordick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Bl\u00e4ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Gockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"1419_CR1","unstructured":"Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut (2019) Datenbankabfrage mit Sch\u00e4tzung der Inzidenz, Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten. www.krebsdaten.de\/abfrage. Zugegriffen: 31. Aug. 2022"},{"key":"1419_CR2","unstructured":"AOK-Bundesverband, Arbeitsgemeinschaft Deutscher Tumorzentren e.\u202fV., Zentrum f\u00fcr Evidenzbasierte Gesundheitsversorgung des Universit\u00e4tsklinikums Carl Gustav Carus Dresden und der Medizinischen Fakult\u00e4t der TU Dresden Gemeinsame Pressemitteilung. https:\/\/aok-bv.de\/imperia\/md\/aokbv\/presse\/pressemitteilungen\/archiv\/2020\/pm_220426_ergebnisse_onkologie_projekt_wizen.pdf. Zugegriffen: 14. Sep. 2022"},{"issue":"1","key":"1419_CR3","first-page":"93","volume":"387","author":"FA Sinicrope","year":"2022","unstructured":"Sinicrope\u00a0FA (2022) The increasing incidence of early-onset colorectal cancer. Reply. N\u00a0Engl J Med 387(1):93\u201394","journal-title":"N Engl J Med"},{"issue":"10352","key":"1419_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GBD 2019 Cancer Risk Factors Collaborators","year":"2022","unstructured":"GBD 2019 Cancer Risk Factors Collaborators (2022) The global burden of cancer attributable to risk factors, 2010\u201319: a\u00a0systematic analysis for the global burden of disease study 2019. Lancet 400(10352):563\u2013591","journal-title":"Lancet"},{"key":"1419_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM198809013190901","volume":"319","author":"B Vogelstein","year":"1988","unstructured":"Vogelstein\u00a0B, Fearon\u00a0ER, Hamilton\u00a0SR et al (1988) Genetic alterations during colorectal-tumor development. N\u00a0Engl J Med 319:525\u2013532","journal-title":"N Engl J Med"},{"key":"1419_CR6","first-page":"101","volume":"113","author":"H Brenner","year":"2016","unstructured":"Brenner\u00a0H, Schrotz-King\u00a0P, Holleczek\u00a0B et al (2016) Declining bowel cancer incidence and mortality in Germany. Dtsch Arztebl Int 113:101\u2013106","journal-title":"Dtsch Arztebl Int"},{"key":"1419_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3238\/arztebl.m2021.0111","volume":"118","author":"R Cardoso","year":"2021","unstructured":"Cardoso\u00a0R, Zhu\u00a0A, Guo\u00a0F, Heisser\u00a0T, Hoffmeister\u00a0M, Brenner\u00a0H (2021) Incidence and mortality of proximal and distal colorectal cancer in Germany-trends in the era of screening colonoscopy. Dtsch Arztebl Int 118:281\u2013287. https:\/\/doi.org\/10.3238\/arztebl.m2021.0111","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"1419_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s\u00a0G, Tabernero\u00a0J, Labianca\u00a0R, Hochhauser\u00a0D, Salazar\u00a0R, Iveson\u00a0T, Laurent-Puig\u00a0P, Quirke\u00a0P, Yoshino\u00a0T, Taieb\u00a0J, Martinelli\u00a0E, Arnold\u00a0D, ESMO Guidelines Committee (2020) Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(10):1291\u20131305","journal-title":"Ann Oncol"},{"key":"1419_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00292-021-01016-6","volume":"43","author":"F M\u00fcller","year":"2022","unstructured":"M\u00fcller\u00a0F, Lugli\u00a0A, Dawson\u00a0H (2022) Tumor Budding beim kolorektalen Karzinom \u2013 Informationen zur klinischen Anwendung und Anleitung zur praktischen Bestimmung. Pathologe 43:45\u201350","journal-title":"Pathologe"},{"issue":"12","key":"1419_CR10","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.annonc.2021.08.1752","volume":"32","author":"T Yoshino","year":"2021","unstructured":"Yoshino\u00a0T, Argil\u00e9s\u00a0G, Oki\u00a0E, Martinelli\u00a0E, Taniguchi\u00a0H, Arnold\u00a0D, Mishima\u00a0S, Li\u00a0Y, Smruti\u00a0BK, Ahn\u00a0JB, Faud\u00a0I, Chee\u00a0CE, Yeh\u00a0KH, Lin\u00a0PC, Chua\u00a0C, Hasbullah\u00a0HH, Lee\u00a0MA, Sharma\u00a0A, Sun\u00a0Y, Curigliano\u00a0G, Bando\u00a0H, Lordick\u00a0F, Yamanaka\u00a0T, Tabernero\u00a0J, Baba\u00a0E, Cervantes\u00a0A, Ohtsu\u00a0A, Peters\u00a0S, Ishioka\u00a0C, Pentheroudakis\u00a0G (2021) Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol 32(12):1496\u20131510","journal-title":"Ann Oncol"},{"issue":"9","key":"1419_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00384-018-3098-3","volume":"33","author":"S Merkel","year":"2018","unstructured":"Merkel\u00a0S, Schellerer\u00a0VS, Wein\u00a0A, Semrau\u00a0S, Geppert\u00a0C, G\u00f6hl\u00a0J, Hohenberger\u00a0W, Weber\u00a0K, Gr\u00fctzmann\u00a0R (2018) The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. Int J Colorectal Dis 33(9):1215\u20131223","journal-title":"Int J Colorectal Dis"},{"issue":"6","key":"1419_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00384-020-03557-3","volume":"35","author":"C Beck","year":"2020","unstructured":"Beck\u00a0C, Weber\u00a0K, Brunner\u00a0M, Agaimy\u00a0A, Semrau\u00a0S, Gr\u00fctzmann\u00a0R, Schellerer\u00a0V, Merkel\u00a0S (2020) The influence of postoperative complications on long-term prognosis in patients with colorectal carcinoma. Int J Colorectal Dis 35(6):1055\u20131066","journal-title":"Int J Colorectal Dis"},{"issue":"13","key":"1419_CR13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey\u00a0A, Sobrero\u00a0AF, Shields\u00a0AF, Yoshino\u00a0T, Paul\u00a0J, Taieb\u00a0J, Souglakos\u00a0J, Shi\u00a0Q, Kerr\u00a0R, Labianca\u00a0R, Meyerhardt\u00a0JA, Vernerey\u00a0D, Yamanaka\u00a0T, Boukovinas\u00a0I, Meyers\u00a0JP, Renfro\u00a0LA, Niedzwiecki\u00a0D, Watanabe\u00a0T, Torri\u00a0V, Saunders\u00a0M, Sargent\u00a0DJ, Andre\u00a0T, Iveson\u00a0T (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N\u00a0Engl J Med 378(13):1177\u20131188","journal-title":"N Engl J Med"},{"key":"1419_CR14","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/s1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9\u00a0T, Meyerhardt\u00a0J, Iveson\u00a0T, Sobrero\u00a0A, Yoshino\u00a0T, Souglakos\u00a0I et\u00a0al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a\u00a0prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620\u20131629. https:\/\/doi.org\/10.1016\/s1470-2045(20)30527-1","journal-title":"Lancet Oncol"},{"key":"1419_CR15","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le\u00a0DT, Uram\u00a0JN, Wang\u00a0H et al (2015) PD\u20111 blockade in tumors with mismatch-repair deficiency. N\u00a0Engl J Med 372:2509\u20132520","journal-title":"N Engl J Med"},{"issue":"25","key":"1419_CR16","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek\u00a0A, Lumish\u00a0M, Sinopoli\u00a0J, Weiss\u00a0J, Shia\u00a0J, Lamendola-Essel\u00a0M, El Dika\u00a0IH, Segal\u00a0N, Shcherba\u00a0M, Sugarman\u00a0R, Stadler\u00a0Z, Yaeger\u00a0R, Smith\u00a0JJ, Rousseau\u00a0B, Argiles\u00a0G, Patel\u00a0M, Desai\u00a0A, Saltz\u00a0LB, Widmar\u00a0M, Iyer\u00a0K, Zhang\u00a0J, Gianino\u00a0N, Crane\u00a0C, Romesser\u00a0PB, Pappou\u00a0EP, Paty\u00a0P, Garcia-Aguilar\u00a0J, Gonen\u00a0M, Gollub\u00a0M, Weiser\u00a0MR, Schalper\u00a0KA, Diaz\u00a0LA Jr. (2022) PD\u20111 blockade in mismatch repair-deficient, locally advanced rectal cancer. N\u00a0Engl J Med 386(25):2363\u20132376","journal-title":"N Engl J Med"},{"issue":"24","key":"1419_CR17","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie\u00a0J, Cohen\u00a0JD, Lahouel\u00a0K, Lo\u00a0SN, Wang\u00a0Y, Kosmider\u00a0S, Wong\u00a0R, Shapiro\u00a0J, Lee\u00a0M, Harris\u00a0S, Khattak\u00a0A, Burge\u00a0M, Harris\u00a0M, Lynam\u00a0J, Nott\u00a0L, Day\u00a0F, Hayes\u00a0T, McLachlan\u00a0SA, Lee\u00a0B, Ptak\u00a0J, Silliman\u00a0N, Dobbyn\u00a0L, Popoli\u00a0M, Hruban\u00a0R, Lennon\u00a0AM, Papadopoulos\u00a0N, Kinzler\u00a0KW, Vogelstein\u00a0B, Tomasetti\u00a0C, Gibbs\u00a0P, DYNAMIC Investigators (2022) Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N\u00a0Engl J Med 386(24):2261\u20132272","journal-title":"N Engl J Med"},{"issue":"22","key":"1419_CR18","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz\u00a0S, Chang\u00a0GJ, Overman\u00a0MJ, Eng\u00a0C, Sargent\u00a0DJ, Larson\u00a0DW, Grothey\u00a0A, Vauthey\u00a0JN, Nagorney\u00a0DM, McWilliams\u00a0RR (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J\u00a0Clin Oncol 27(22):3677\u20133683","journal-title":"J Clin Oncol"},{"issue":"2","key":"1419_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand\u00a0C, Andr\u00e9\u00a0T, Achille\u00a0E, Lledo\u00a0G, Flesh\u00a0M, Mery-Mignard\u00a0D, Quinaux\u00a0E, Couteau\u00a0C, Buyse\u00a0M, Ganem\u00a0G, Landi\u00a0B, Colin\u00a0P, Louvet\u00a0C, de Gramont\u00a0A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a\u00a0randomized GERCOR study. J\u00a0Clin Oncol 22(2):229\u2013237","journal-title":"J Clin Oncol"},{"key":"1419_CR20","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini\u00a0C, Loupakis\u00a0F, Antoniotti\u00a0C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306\u20131315","journal-title":"Lancet Oncol"},{"key":"1419_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2016.07.019","volume":"67","author":"V Heinemann","year":"2016","unstructured":"Heinemann\u00a0V, Rivera\u00a0F, O\u2019Neil\u00a0BH, Stintzing\u00a0S, Koukakis\u00a0R, Terwey\u00a0JH, Douillard\u00a0JY (2016) A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer 67:11\u201320","journal-title":"Eur J Cancer"},{"issue":"8","key":"1419_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40265-018-0921-7","volume":"78","author":"C Gallois","year":"2018","unstructured":"Gallois\u00a0C, Pernot\u00a0S, Zaanan\u00a0A, Taieb\u00a0J (2018) Colorectal cancer: why does side matter? Drugs 78(8):789\u2013798","journal-title":"Drugs"},{"issue":"4","key":"1419_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/PPO.0000000000000328","volume":"24","author":"K Mody","year":"2018","unstructured":"Mody\u00a0K, Baldeo\u00a0C, Bekaii-Saab\u00a0T (2018) Antiangiogenic therapy in colorectal cancer. Cancer\u00a0J 24(4):165\u2013170","journal-title":"Cancer J"},{"key":"1419_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey\u00a0A, Van Cutsem\u00a0E, Sobrero\u00a0A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"1419_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer\u00a0RJ, Van Cutsem\u00a0E, Falcone\u00a0A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N\u00a0Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"1419_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/EDBK_200929","volume":"38","author":"R Dienstmann","year":"2018","unstructured":"Dienstmann\u00a0R, Salazar\u00a0R, Tabernero\u00a0J (2018) Molecular subtypes and the evolution of treatment decisions in metastatic colorectal cancer. Am Soc Clin Oncol Educ Book 38:231\u2013238","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"17","key":"1419_CR27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz\u00a0S, Grothey\u00a0A, Yaeger\u00a0R, Van Cutsem\u00a0E, Desai\u00a0J, Yoshino\u00a0T, Wasan\u00a0H, Ciardiello\u00a0F, Loupakis\u00a0F, Hong\u00a0YS, Steeghs\u00a0N, Guren\u00a0TK, Arkenau\u00a0HT, Garcia-Alfonso\u00a0P, Pfeiffer\u00a0P, Orlov\u00a0S, Lonardi\u00a0S, Elez\u00a0E, Kim\u00a0TW, Schellens\u00a0JHM, Guo\u00a0C, Krishnan\u00a0A, Dekervel\u00a0J, Morris\u00a0V, Calvo Ferrandiz\u00a0A, Tarpgaard\u00a0LS, Braun\u00a0M, Gollerkeri\u00a0A, Keir\u00a0C, Maharry\u00a0K, Pickard\u00a0M, Christy-Bittel\u00a0J, Anderson\u00a0L, Sandor\u00a0V, Tabernero\u00a0J (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N\u00a0Engl J Med 381(17):1632\u20131643","journal-title":"N Engl J Med"},{"issue":"23","key":"1419_CR28","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9\u00a0T, Shiu\u00a0KK, Kim\u00a0TW, Jensen\u00a0BV, Jensen\u00a0LH, Punt\u00a0C, Smith\u00a0D, Garcia-Carbonero\u00a0R, Benavides\u00a0M, Gibbs\u00a0P, de la Fouchardiere\u00a0C, Rivera\u00a0F, Elez\u00a0E, Bendell\u00a0J, Le\u00a0DT, Yoshino\u00a0T, Van Cutsem\u00a0E, Yang\u00a0P, Farooqui\u00a0MZH, Marinello\u00a0P, Diaz\u00a0LA Jr, KEYNOTE-177 Investigators. (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N\u00a0Engl J Med 383(23):2207\u20132218","journal-title":"N Engl J Med"},{"key":"1419_CR29","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo\u00a0J, Chakravarty\u00a0D, Dienstmann\u00a0R, Jezdic\u00a0S, Gonzalez-Perez\u00a0A, Lopez-Bigas\u00a0N, Ng\u00a0CKY, Bedard\u00a0PL, Tortora\u00a0G, Douillard\u00a0JY, Van Allen\u00a0EM, Schultz\u00a0N, Swanton\u00a0C, Andr\u00e9\u00a0F, Pusztai\u00a0L (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol 29:1895\u20131902","journal-title":"Ann Oncol"},{"key":"1419_CR30","unstructured":"https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/kolonkarzinom\/@@guideline\/html\/index.html. Zugegriffen: 14. Sep. 2022"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01419-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:28:48Z","timestamp":1669310928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01419-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01419-4","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"26 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Lordick: Pers\u00f6nliche Honorare von Amgen, Astellas, AstraZeneca, Bayer, BioNTech, BMS, Daiichi Sankyo, Eli Lilly, Elsevier, Falk Foundation, Incyte, Medscape, MedUpdate GmbH, Merck, MSD, Novartis, Roche, Servier, Springer Nature, streamedup!. Institutionelle Forschungsunterst\u00fctzung durch Astellas, BMS, Gilead, MSD. U.\u00a0Hacker, A.\u00a0Hoffmeister, H.\u00a0Bl\u00e4ker und I.\u00a0Gockel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}